

OncoTherapy Science, Inc.

December 6, 2016

Announcement of milestone payment for the progress of Phase III clinical trial of the
cancer-specific peptide vaccine S-588410

OncoTherapy Science, Inc. (President & CEO: Masaharu Mori; hereinafter, “OncoTherapy”) announces that OncoTherapy has received notification of the achievement of a milestone from Shionogi & Co., Ltd. (Head office: Chuo-ku, Osaka, President and CEO: Isao Teshirogi) , pursuant to the agreement of February 23, 2015 between the both parties, in connection with the progress of the Phase III clinical trial of the cancer-specific peptide vaccine S-588410 for esophageal cancer which OncoTherapy has out-licensed to Shionogi.

This milestone will be recorded as operating revenue in the third quarter of the fiscal year of 2016.